Should intermittent androgen deprivation be used in routine clinical practice?

For several decades, androgen deprivation (AD) has been the mainstay for treating metastatic prostate cancer. AD can be attained by a variety of means; however, irrespective of modality and a gratifying initial high response rate, almost all patients advance to a state of androgen independence and ultimately a hormone-refractory state. Improved understanding of the biology and mechanisms of progression to androgen independence coupled with promising preclinical data have led to investigating intermittent AD (IAD) as a way of improving disease control while maintaining quality of life. Preliminary published clinical experience, mostly from uncontrolled trials, suggests the feasibility of this approach. Two ongoing cooperative-group phase III trials are evaluating the survival impact of IAD both in patients with metastatic disease and in those with prostate-specific antigen failure post-radiation therapy. There are several unanswered questions regarding this approach, and until more definitive data regarding its safety and impact on survival are available, IAD should be considered experimental. In this review, we detail the background and preclinical scientific rational for investigating IAD, and we review published clinical experience and describe the ongoing phase III clinical trials. We also discuss special considerations for using IAD outside the context of a clinical trial.

[1]  E. Small,et al.  Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. , 2002, The Journal of urology.

[2]  T. Shanafelt,et al.  Andropause: symptom management for prostate cancer patients treated with hormonal ablation. , 2003, The oncologist.

[3]  N. Bruchovsky,et al.  Hormonal effects on cell proliferation in rat prostate. , 1975, Vitamins and hormones.

[4]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[5]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[6]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[7]  N. Bruchovsky,et al.  Prostate cancer: molecular biology of early progression to androgen independence. , 1999, Endocrine-related cancer.

[8]  D. Tindall,et al.  Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.

[9]  D. Mcleod,et al.  Hormonal therapy: historical perspective to future directions. , 2003, Urology.

[10]  D. Petrylak,et al.  Clinical trials in metastatic prostate cancer--has there been real progress in the past decade? , 2005, European journal of cancer.

[11]  H. Klocker,et al.  Long‐term androgen‐ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells , 2004, The Prostate.

[12]  M. Gleave,et al.  Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. , 1995, Urology.

[13]  Wu Cp,et al.  The prostate in eunuchs. , 1991 .

[14]  U. Tunn.  Intermittent endocrine therapy of prostate cancer. , 1996, European urology.

[15]  P. Carroll,et al.  Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. , 2001, Urology.

[16]  R. Owen,et al.  Observations on Certain Parts of the Animal Economy, Inclusive of Several Papers from the Philosophical Transactions, &c. , 1839, The British and Foreign Medical Review.

[17]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[18]  J. W. White.  II. The Present Position of the Surgery of the Hypertrophied Prostate. , 1893, Annals of surgery.

[19]  G. Theyer,et al.  Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. , 1997, British Journal of Cancer.

[20]  J. Crook,et al.  Intermittent androgen suppression in the management of prostate cancer. , 1999, Urology.

[21]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[22]  W. Whitmore.  The natural history of prostatic cancer , 1973, Progress in clinical and biological research.

[23]  D. S. Coffey,et al.  Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. , 1981, Cancer research.

[24]  T. Jacks,et al.  Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. T. Cabot.  II. The Question of Castration for Enlarged Prostate. , 1896, Annals of surgery.

[26]  L. Denis,et al.  Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer , 1993, Cancer.

[27]  Gu Fl,et al.  The prostate 41-65 years post castration. An analysis of 26 eunuchs. , 1987 .

[28]  H. Bonkhoff,et al.  Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model , 1996, The Prostate.

[29]  L. Klotz,et al.  Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.

[30]  A. De la taille,et al.  Intermittent androgen suppression in patients with prostate cancer , 2003, BJU international.

[31]  F. Sierra,et al.  Fetoscopic placement of a transurethral stent for intrauterine obstructive uropathy. , 2004, The Journal of urology.

[32]  M. Scholz,et al.  Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. , 2000, The oncologist.

[33]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[34]  W. Ellis,et al.  Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. , 1996, Urology.

[35]  G. Williams,et al.  Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. , 1997, Urology.

[36]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[37]  U. Tunn,et al.  1458: Intermittent Is as Effective as Continuous Androgen Deprivation in Patients with PSA-Relapse after Radical Prostatectomy (RP) , 2004 .

[38]  D. Dearnaley,et al.  A pilot study of intermittent androgen deprivation in advanced prostate cancer. , 1998, British journal of urology.